241 related articles for article (PubMed ID: 11086225)
1. Development of vaccines for prevention of botulism.
Byrne MP; Smith LA
Biochimie; 2000; 82(9-10):955-66. PubMed ID: 11086225
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
Khouri JM; Motter RN; Arnon SS
Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
[TBL] [Abstract][Full Text] [Related]
4. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
[TBL] [Abstract][Full Text] [Related]
6. Vaccines against botulism.
Karalewitz AP; Barbieri JT
Curr Opin Microbiol; 2012 Jun; 15(3):317-24. PubMed ID: 22694934
[TBL] [Abstract][Full Text] [Related]
7. Botulism and vaccines for its prevention.
Smith LA
Vaccine; 2009 Nov; 27 Suppl 4():D33-9. PubMed ID: 19837283
[TBL] [Abstract][Full Text] [Related]
8. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
9. Botulinum neurotoxin vaccines: past, present, and future.
Smith LA; Rusnak JM
Crit Rev Immunol; 2007; 27(4):303-18. PubMed ID: 18197811
[TBL] [Abstract][Full Text] [Related]
10. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
11. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA
Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341
[TBL] [Abstract][Full Text] [Related]
12. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
Yu YZ; Guo JP; An HJ; Zhang SM; Wang S; Yu WY; Sun ZW
Vaccine; 2013 May; 31(20):2427-32. PubMed ID: 23583890
[TBL] [Abstract][Full Text] [Related]
13. New targets in the search for preventive and therapeutic agents for botulism.
Anniballi F; Lonati D; Fiore A; Auricchio B; De Medici D; Locatelli CA
Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1075-86. PubMed ID: 25089560
[TBL] [Abstract][Full Text] [Related]
14. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
[TBL] [Abstract][Full Text] [Related]
15. Development of recombinant vaccines for botulinum neurotoxin.
Smith LA
Toxicon; 1998 Nov; 36(11):1539-48. PubMed ID: 9792170
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
[TBL] [Abstract][Full Text] [Related]
17. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
[TBL] [Abstract][Full Text] [Related]
18. Production of recombinant botulism antigens: a review of expression systems.
Moreira GM; Cunha CE; Salvarani FM; Gonçalves LA; Pires PS; Conceição FR; Lobato FC
Anaerobe; 2014 Aug; 28():130-6. PubMed ID: 24930432
[TBL] [Abstract][Full Text] [Related]
19. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.
Clayton MA; Clayton JM; Brown DR; Middlebrook JL
Infect Immun; 1995 Jul; 63(7):2738-42. PubMed ID: 7790092
[TBL] [Abstract][Full Text] [Related]
20. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system.
Lee JS; Pushko P; Parker MD; Dertzbaugh MT; Smith LA; Smith JF
Infect Immun; 2001 Sep; 69(9):5709-15. PubMed ID: 11500447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
